MediWound Investor Relations Material

MediWound Ltd. specializes in the development, manufacture, and commercialization of innovative therapies for tissue repair and regeneration. The company focuses primarily on enzymatic debridement solutions for the treatment of severe burns, chronic wounds, and other hard-to-heal injuries. MediWound's proprietary technologies are designed to improve the healing process by selectively removing dead or damaged tissue without harming surrounding healthy tissue. The company serves healthcare providers, hospitals, and wound care centers globally, aiming to enhance patient outcomes and reduce treatment costs. MediWound is headquartered in Yavne, Israel, and its shares are listed on the NASDAQ.